eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2024-03-30 21 1 317 324 10.13005/bbra/3227 50421 article Neha Manish Munot 1 Maheshwari Tulsidas Raut 2 Ujjwala Yadav Kandekar 3 Neeta Rai 4 Preeti Vinod Gaikwad 5 Rajmata Jijau Shikshan Prasarak Mandal’s College of Pharmacy, Pune, India Department of Pharmaceutics, Smt. Kashibai Navale College of Pharmacy, Pune, India Department of Pharmaceutics, JSPMs Rajarshi Shahu College of Pharmacy and Research, Pune, India Department of Pharmaceutics,School of Pharmacy, Vishwakarma University, Pune, India Department of Pharmaceutical Chemistry, KJEI’ Trinity College of Pharmacy, Pune, Maharashtra, India In the past couple of years, the world has been dealing with a dreadful pandemic known as Covid-19 along with one of the life-threatening infection i.e. mucormycosis. Mucormycosis (Zygomycosis) is a fungal infection caused by a group of molds called mucormycosis. Several clinical cases of mucormycosis have been reported globally during the Covid-19 pandemic. Patients with compromised immunity or uncontrolled diabetics or patients that were given steroid therapy to combat infection due to corona virus were at high risk of acquiring mucormycosis as co-morbidity associated with Covid-19. In the present review, various types of mucormycosis, diagnosis, and treatment strategies are explained as it is associated with high morbidity and mortality. Amphotericin B liposomal formulation was found to be the most widely used to treat mucormycosis. Other antifungal agents and adjuvant therapies were also tried to treat this infection. https://www.biotech-asia.org/vol21no1/comprehensive-review-on-covid-19-associated-mucormycosis-diagnosis-types-and-treatment/ Antifungal drugs; Mucormycosis (zygomycosis); rhino cerebral sinus